Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 181-189 , April 2010

The Utility of Changes in Serum Levels of C-Terminal Telopeptide of Type I Collagen in Predicting Patient Response to Oral Monthly Ibandronate Therapy

Portions of this work have been presented at the following meetings: 7th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, Porto, Portugal, March 28–31, 2007; 16th Annual Meeting & Clinical Congress, American Association of Clinical Endocrinologists, Seattle, WA, USA, April 11–15, 2007; 7th International Symposium on Osteoporosis, National Osteoporosis Foundation, Washington, DC, USA, April 18–22, 2007.

  • Marc C. Hochberg

      Affiliations

    • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    • Corresponding Author InformationAddress correspondence to: Marc C. Hochberg, MD, MPH, Division of Rheumatology & Clinical Immunology, Department of Medicine, University of Maryland School of Medicine, 10 S. Pine Street, MSTF 8-34, Baltimore, MD 21201.
    • ,
  • Stuart L. Silverman

      Affiliations

    • Cedars-Sinai/UCLA and OMC Clinical Research Center, Beverly Hills, CA, USA
    • ,
  • Charles E. Barr

      Affiliations

    • Roche, Nutley, NJ, USA
    • ,
  • Paul D. Miller

      Affiliations

    • Colorado Center for Bone Research, Lakewood, CO, USA

Received 6 May 2009 ,Revised 1 October 2009 ,Accepted 10 January 2010.

References 

  1. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006;119:S25–31
  2. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999;84:2363–2368
  3. Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab. 1993;76:1399–1406
  4. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999;24:237–244
  5. Ravn P, Thompson DE, Ross PD, Christiansen C. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone. 2003;33:150–158
  6. Greenspan SL, Parker RA, Ferguson L, et al. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431–1438
  7. Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab. 2000;85:3537–3540
  8. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 1998;44:2290–2300
  9. Rosen HN, Moses AC, Garber J, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66:100–103
  10. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315–1322
  11. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654–661
  12. Bjarnason NH, Henriksen EE, Alexandersen P, et al. Mechanism of circadian variation in bone resorption. Bone. 2002;30:307–313
  13. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31:57–61
  14. Bonnick SL, Johnston CC, Kleerekoper M, et al. Importance of precision in bone density measurements. J Clin Densitom. 2001;4:105–110
  15. Sebba AI, Bonnick SL, Kagan R, et al. Response to therapy with once-weekly alendronate 70mg compared to once-weekly risedronate 35mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin. 2004;20:2031–2041
  16. Chen YT, Miller PD, Barrett-Connor E, et al. An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int. 2007;18:1287–1296
  17. Girman CJ, Chandler JM, Zimmerman SI, et al. Prediction of fracture in nursing home residents. J Am Geriatr Soc. 2002;50:1341–1347
  18. Jin H, Lu Y, Harris ST, et al. Classification algorithms for hip fracture prediction based on recursive partitioning methods. Med Decis Making. 2004;24:386–398
  19. Miller PD, Barlas S, Brenneman SK, et al. An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med. 2004;164:1113–1120
  20. Quartararo M, Glasziou P, Kerr CB. Classification trees for decision making in long-term care. J Gerontol A Biol Sci Med Sci. 1995;50:M298–302
  21. Miller PD, Baran DT, Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: consensus of an expert panel. J Clin Densitom. 1999;2:323–342
  22. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91:1370–1375
  23. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962–970
  24. Rosen CJ, Chesnut CH, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904–1910
  25. Kim SW, Park DJ, Park KS, et al. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J. 2005;52:667–674
  26. Looker AC, Bauer DC, Chesnut CH, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int. 2000;11:467–480
  27. Akesson K, Kakonen SM, Josefsson PO, et al. Fracture-induced changes in bone turnover: a potential confounder in the use of biochemical markers in osteoporosis. J Bone Miner Metab. 2005;23:30–35
  28. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11:337–349
  29. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47:694–702
  30. Zaidi M, Epstein S, Friend K. Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. Ann N Y Acad Sci. 2006;1068:560–563
  31. Greenspan SL, Dresner-Pollak R, Parker RA, et al. Diurnal variation of bone mineral turnover in elderly men and women. Calcif Tissue Int. 1997;60:419–423
  32. Schlemmer A, Ravn P, Hassager C, Christiansen C. Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. Bone. 1997;20:63–67
  33. Glover SJ, Garnero P, Naylor K, et al. Establishing a reference range for bone turnover markers in young, healthy women. Bone. 2008;42:623–630
  34. U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General; 2004;
  35. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006;119:S32–37
  36. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92:1296–1304

 Funding sources: This research was funded by Roche.

 Conflicts of interest. Dr. Hochberg has served as a consultant for Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble, Roche, and Wyeth. Dr. Silverman has received grants or research support from Lilly, Merck, Novartis, Procter & Gamble, Roche, and Wyeth. and has acted as a consultant or speaker for Amgen, Lilly, GlaxoSmithKline, and Merck. Dr. Barr is an employee of Roche. Dr. Miller has received scientific grants from Procter & Gamble, sanofi-aventis, Roche, Eli Lilly, Merck, Novartis, and Amgen. He has served on speaker boards, advisory boards or as a consultant for Procter & Gamble, sanofi-aventis, Merck, Eli Lilly, Amgen, NPS, Novartis, Roche, and GlaxoSmithKline.

PII: S1094-6950(10)00008-9

doi: 10.1016/j.jocd.2010.01.007

Journal of Clinical Densitometry
Volume 13, Issue 2 , Pages 181-189 , April 2010

Article Tools

* Image Usage & Resolution